A case study of stable disease after hepatic arterial infusion chemotherapy in a patient with systemic chemotherapy-resistant unresectable hepatic metastases of colon cancer

The patient was a 72-year-old man with cancer of the descending colon accompanied by multiple unresectable hepatic metastases. As first-line systemic chemotherapy, mFOLFOX6, anti-vascular endothelial growth factor (VEGF) antibody+FOLFIRI, and anti-epidermal growth factor receptor (EGFR) antibody+CPT-11 were administered in order mentioned. However, recurrent hepatic metastasis was exacerbated. As fourth-line chemotherapy, the patient received hepatic arterial infusion chemotherapy (HAIC) with 5-FU and LV. The chemotherapy regimen consisted of 5-FU 600 mg/m2 and LV 250 mg/m2 given once a week. After 6 weeks, CT revealed that the multiple liver metastases had not increased, and the level of the tumor marker CA19-9 significantly decreased from 1,980 (normal range, 0-37 U/mL)to 942.9 U/mL. HAIC was continued, and the patient maintained an excellent PS for 3.5 months. We report a case of stable disease in response to HAIC in a patient who exhibited resistance to systemic chemotherapy with an anti-EGFR antibody, an anti-EGFR antibody, mFOLFOX6, and FOLFIRI.